This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kyriakopoulos CE , Chen YH , Carducci MA , Liu G , Jarrard DF , Hahn NM , Shevrin DH , Dreicer R , Hussain M , Eisenberger M , Kohli M , Plimack ER , Vogelzang NJ , Picus J , Cooney MM , Garcia JA , DiPaola RS , Sweeney CJ
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
J Clin Oncol. 2018 Apr 10;36(11) :1080-1087
PMID: 29384722 PMCID: PMC5891129
AbstractPurpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) trial with more mature follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostate cancer were equally randomly assigned to receive either ADT in combination with docetaxel 75 mg/m(2) for up to six cycles or ADT alone. The primary end point of the study was overall survival (OS). Additional analyses of the prospectively defined low- and high-volume disease subgroups were performed. High-volume disease was defined as presence of visceral metastases and/or >/= four bone metastases with at least one outside of the vertebral column and pelvis. Results At a median follow-up of 53.7 months, the median OS was 57.6 months for the chemohormonal therapy arm versus 47.2 months for ADT alone (hazard ratio [HR], 0.72; 95% CI, 0.59 to 0.89; P = .0018). For patients with high-volume disease (n = 513), the median OS was 51.2 months with chemohormonal therapy versus 34.4 months with ADT alone (HR, 0.63; 95% CI, 0.50 to 0.79; P < .001). For those with low-volume disease (n = 277), no OS benefit was observed (HR, 1.04; 95% CI, 0.70 to 1.55; P = .86). Conclusion The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patients with low-volume disease, no OS benefit was discerned.
Notes1527-7755 Kyriakopoulos, Christos E Chen, Yu-Hui Carducci, Michael A Liu, Glenn Jarrard, David F Hahn, Noah M Shevrin, Daniel H Dreicer, Robert Hussain, Maha Eisenberger, Mario Kohli, Manish Plimack, Elizabeth R Vogelzang, Nicholas J Picus, Joel Cooney, Matthew M Garcia, Jorge A DiPaola, Robert S Sweeney, Christopher J UG1 CA189829/CA/NCI NIH HHS/United States P50 CA180995/CA/NCI NIH HHS/United States U10 CA180802/CA/NCI NIH HHS/United States U10 CA180821/CA/NCI NIH HHS/United States U10 CA180801/CA/NCI NIH HHS/United States U10 CA180795/CA/NCI NIH HHS/United States U10 CA180847/CA/NCI NIH HHS/United States U10 CA180790/CA/NCI NIH HHS/United States U10 CA180820/CA/NCI NIH HHS/United States U10 CA180833/CA/NCI NIH HHS/United States U10 CA180794/CA/NCI NIH HHS/United States U10 CA180799/CA/NCI NIH HHS/United States U10 CA180867/CA/NCI NIH HHS/United States U10 CA180888/CA/NCI NIH HHS/United States U10 CA180853/CA/NCI NIH HHS/United States Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.